<qa>  What is the purpose of the Phase 2a study?This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous SC doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis RA who have had an inadequate response to therapy with disease-modifying anti rheumatic drugs DMARDs and who may have undergone anti-TNF therapy. This study will assist with dose selection for further planned Phase 2 studies. 